EverSource Wealth Advisors’s Filana Therapeutics FLNA Stock Holding History

EverSource Wealth Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506	Sell	425 -2,134	-83%	-$3.04K	﹤0.01%	4127
2026 Q1	$4.32K	Sell	2,559 -551	-18%	-$1.13K	﹤0.01%	3334
2025 Q4	$6.16K	Sell	3,110 -659	-17%	-$2.11K	﹤0.01%	3035
2025 Q3	$11K	Buy	3,769 +1,059	+39%	+$2.44K	﹤0.01%	2774
2025 Q2	$4.91K	Buy	2,710 +2,213	+445%	+$3.94K	﹤0.01%	3167
2025 Q1	$746	Buy	497 +52	+12%	+$131	﹤0.01%	3331
2024 Q4	$1.05K	Buy	445 +153	+52%	+$2.69K	﹤0.01%	2948
2024 Q3	$8.59K	Buy	292 +207	+244%	+$4.77K	﹤0.01%	1952
2024 Q2	$1.89K	Hold	85	–	–	﹤0.01%	2568
2024 Q1	$1.88K	Buy	85 +80	+1,600%	+$1.84K	﹤0.01%	2408
2023 Q4	$113	Hold	5	–	–	﹤0.01%	2593
2023 Q3	$83	Hold	5	–	–	﹤0.01%	2458
2023 Q2	$123	Hold	5	–	–	﹤0.01%	2438
2023 Q1	$121	Hold	5	–	–	﹤0.01%	2329
2022 Q4	$148	Hold	5	–	–	﹤0.01%	2266
2022 Q3	$0	Hold	5	–	–	﹤0.01%	2110
2022 Q2	$0	Hold	5	–	–	﹤0.01%	1865
2022 Q1	$0	Hold	5	–	–	﹤0.01%	1826
2021 Q4	$0	Buy	+5	New	+$262	﹤0.01%	1775

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

EverSource Wealth Advisors's FLNA Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Filana Therapeutics (FLNA) stake by 83% in Q2 2026, selling an estimated $3.04K and leaving 425 shares worth $506. The position accounts for ﹤0.01% of the portfolio, ranked #4127.

EverSource Wealth Advisors first reported a position in FLNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $11K in Q3 2025. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

EverSource Wealth Advisors held 425 shares of Filana Therapeutics worth $506 as of Q2 2026.
EverSource Wealth Advisors sold 2,134 Filana Therapeutics shares in Q2 2026, an estimated $3.04K.
Filana Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4127 holding.
EverSource Wealth Advisors first reported a position in Filana Therapeutics in Q4 2021 and has held it in 19 quarters since.
EverSource Wealth Advisors's Filana Therapeutics position peaked at $11K in Q3 2025.
84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.